Why is vbl share price falling

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: VBL Therapeutics' share price has been falling primarily due to disappointing clinical trial results for its lead drug candidate VB-111. In October 2021, the company announced that VB-111 failed to meet its primary endpoint in a Phase 3 trial for recurrent glioblastoma, causing the stock to drop approximately 70% in a single day. Following this setback, VBL announced in March 2022 that it would discontinue development of VB-111 and focus on its other pipeline assets, leading to further declines. As of late 2022, VBL's stock had fallen over 90% from its 2021 highs, trading below $1 per share.

Key Facts

VBL Therapeutics' stock dropped approximately 70% on October 18, 2021 after VB-111 failed its Phase 3 glioblastoma trial
The company announced discontinuation of VB-111 development on March 28, 2022
VBL's stock price fell over 90% from its 2021 peak of around $4.50 to below $0.50 by late 2022
VB-111 was VBL's lead candidate representing the company's primary value driver
The Phase 3 trial failure triggered multiple analyst downgrades and reduced price targets

Overview

VBL Therapeutics (NASDAQ: VBLT) is a clinical-stage biotechnology company founded in 2000 and headquartered in Israel. The company focuses on developing targeted therapies for cancer and immune-inflammatory diseases using its proprietary Vascular Targeting System (VTS) platform. VBL's lead candidate was VB-111 (ofranergene obadenovec), a gene therapy designed to target tumor blood vessels. Prior to its Phase 3 failure, VB-111 had shown promise in earlier trials, receiving Fast Track designation from the FDA for recurrent glioblastoma and orphan drug designation for ovarian cancer. The company went public in 2014 through a reverse merger and had raised approximately $150 million in funding rounds before its clinical setback. VBL's pipeline also includes VB-600 series for inflammatory diseases and MOSPD2-targeted antibodies, but these represented earlier-stage assets with less established value propositions compared to VB-111.

How It Works

The decline in VBL's share price followed a clear mechanism typical of biotechnology companies facing clinical trial failures. First, the October 2021 announcement that VB-111 failed to demonstrate statistically significant improvement in overall survival compared to standard care in the Phase 3 OVAL trial triggered immediate investor panic. This 70% single-day drop reflected the market's reassessment of VBL's valuation, which had been heavily weighted toward VB-111's potential. Second, the subsequent decision to discontinue VB-111 development in March 2022 eliminated the company's nearest-term potential revenue source, causing further declines. Third, the stock entered a downward spiral as institutional investors reduced positions, trading volume decreased, and the company faced potential delisting risks from Nasdaq due to trading below $1. Finally, without a clear path to near-term commercialization, VBL's remaining pipeline required additional funding for development, creating dilution concerns that further pressured the stock price.

Why It Matters

The VBL share price decline matters significantly for multiple stakeholders. For investors, it demonstrates the high-risk nature of biotechnology investing, where single clinical trial results can destroy most of a company's market value. For the broader biotech sector, VBL's experience highlights the challenges of developing novel cancer therapies and the importance of diversified pipelines. For patients, the failure represents a setback in glioblastoma treatment options, though VBL continues developing other candidates. The company's survival now depends on its ability to pivot to earlier-stage assets, secure additional funding, and potentially pursue partnerships or strategic alternatives. VBL's experience serves as a case study in biotech valuation volatility and the critical importance of clinical trial design and execution in determining company fate.